Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Interest Expenses (2024)

Kairos Pharma's Interest Expenses history spans 1 years, with the latest figure at $537000.0 for Q3 2024.

  • For Q3 2024, Interest Expenses changed N/A year-over-year to $537000.0; the TTM value through Jun 2025 reached $537000.0, changed N/A, while the annual FY2024 figure was $35000.0, 16.67% down from the prior year.
  • Interest Expenses reached $537000.0 in Q3 2024 per KAPA's latest filing, up from $12000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $537000.0 in Q3 2024 to a low of $12000.0 in Q2 2024.